RAIA DROGASIL SA-SPON ADR Business Summary

RD Saúde (Raia Drogasil SA), trading as the ADR RADLY in the U.S., is the preeminent healthcare retailer in Latin America, operating a network of over 3,600 pharmacies across all 27 Brazilian states under the Raia and Drogasil brands. The company generates revenue through a high-volume transactional model centered on three primary segments: Medicines (prescription and OTC), Perfumery/Personal Care, and Health Services. As of mid-2026, RD Saúde has solidified its market dominance with a national market share of approximately 19.6%, bolstered by a robust omnichannel strategy where digital sales via proprietary apps account for over 30% of total retail revenue. Following the strategic divestment of its 4Bio specialty pharmacy unit in early 2026, the company has pivoted toward an integrated health provider model, leveraging its physical footprint to offer clinical services and wellness programs. Its primary direct competitors include Grupo DPSP, Pague Menos, and Farmácias São João, against whom RD Saúde maintains a premium market position characterized by superior logistics, a 91% Net Promoter Score (NPS), and industry-leading profitability margins. The company's leadership is currently spearheaded by CEO Renato Cepollina Raduan, who assumed the role in January 2025 after serving as Executive Vice President of Pharmacy Operations and Expansion. Raduan is supported by Chairman Marcílio D’Amico Pousada, the former long-standing CEO who transitioned to the board in 2025 to oversee strategic governance. Key executive roles include Antonio Carlos Coelho as VP of Finance and Administrative (CFO) and Marcello De Zagottis as Chief Operating Officer. RD Saúde was formed in 2011 through the landmark merger of Droga Raia and Drogasil, two century-old institutions founded by the Pipponzi and Pires Oliveira Dias families, respectively. These founding families remain central to the company’s governance, controlling approximately 25% of the shares through a long-term shareholders' agreement valid until 2031, while the remaining 75% constitutes a high-liquidity free float held by major institutional investors on the B3 and U.S. OTC markets.